首页> 美国卫生研究院文献>Cancer Biology Therapy >β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells
【2h】

β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells

机译:β-肾上腺素能受体抑制Rap1B异戊二烯化并促进乳腺癌细胞的转移表型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A greater understanding of the molecular basis of breast cancer metastasis will lead to identification of novel therapeutic targets and better treatments. Rap1B is a small GTPase that suppresses the metastasis of breast cancer cells by increasing cell-cell adhesion. In breast cancer, a decrease in Rap1B prenylation and subsequent loss of Rap1B at the plasma membrane decreases cell-cell adhesion and increases cell scattering, which promotes the metastatic phenotype. Protein kinase A (PKA) was recently found to phosphorylate Rap1B and inhibit its prenylation. PKA is activated by G protein-coupled receptors (GPCR) that stimulate Gαs. In this study, we investigated whether the general Gαs activator, cholera toxin, and agonists of the β-adrenergic receptor (βAR), which is a Gαs-coupled GPCR, promote Rap1B phosphorylation and inhibit its prenylation. We show here that cholera toxin and βAR activation phosphorylate Rap1B and inhibit its prenylation and membrane localization, reducing cell-cell adhesion and promoting cell scattering. Furthermore, we report that breast cancer cell migration is decreased by the FDA-approved β-blocker, propranolol. Pharmacological targeting of GPCRs, especially those such as the βAR that are regulated by FDA-approved drugs, to increase cell adhesion and decrease cell scattering could provide a promising therapeutic approach to reduce breast cancer metastasis.
机译:对乳腺癌转移的分子基础的更深入的了解将导致鉴定新的治疗靶标和更好的治疗方法。 Rap1B是一种小的GTP酶,可通过增加细胞粘附来抑制乳腺癌细胞的转移。在乳腺癌中,Rap1B异戊二烯化的减少和随后Rap1B在质膜的丢失会减少细胞间粘附并增加细胞散射,从而促进转移表型。最近发现蛋白激酶A(PKA)使Rap1B磷酸化并抑制其异戊二烯化。 PKA由刺激Gαs的G蛋白偶联受体(GPCR)激活。在这项研究中,我们调查了一般的Gαs激活剂,霍乱毒素和β-肾上腺素能受体(βAR)的激动剂(一种Gαs偶联的GPCR)是否能促进Rap1B磷酸化并抑制其异戊烯基化。我们在这里显示霍乱毒素和βAR激活磷酸化Rap1B,并抑制其异戊二烯化和膜定位,减少细胞间粘附并促进细胞散射。此外,我们报道了FDA批准的β受体阻滞剂普萘洛尔可减少乳腺癌细胞的迁移。 GPCR的药理靶向作用,尤其是那些由FDA批准的药物调节的βAR,如增加细胞粘附力和减少细胞散射的药物,可以提供减少乳腺癌转移的有前途的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号